This is a single center, prospective study to assess the efficacy and safety of using stereotactic body radiation therapy (SBRT) as bridging treatment for hepatocellular carcinoma (HCC) patients on transplant waitlist.
The study population includes patients 18 years of age or older with HCC, who are accepted on waiting list for deceased donor liver transplantation (DDLT). Patient will be assessed in a multidisciplinary committee and they will receive SBRT unless otherwise contraindicated. Patients will undergo SBRT under standard protocol. Patients with HCC beyond University of California, San Francisco criteria (UCSF) will be removed from waitlist.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Radiation dose of 27.5-50Gy in 5 fractions over 5-14 days with a radical dose as high as achievable based on mean liver dose (MLD), while fulfilling the dose constraints of OARs
Queen Mary Hospital
Hong Kong, Hong Kong
RECRUITINGRisk of classical radiation induced liver disease (RILD) after SBRT
Defined as elevated liver transaminases \>5 times of upper normal limit or worsening of Child's score by \>2 within 3 months after SBRT
Time frame: From time of SBRT to 3 months afterwards
Rate of transplant complication
Perioperative complication will be assessed according to Clavien-Dindo classification
Time frame: From time of transplant to 1 months afterwards
Rate of dropout from transplant waitlist
All HCC patients on waitlist will be assessed regularly and will be removed from waitlist if HCC stage is beyond UCSF criteria.
Time frame: From time of enrolment to up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.